ClinicalTrials.gg
TerminatedNCT05501574Updated Jan 6, 2025

An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients

A Phase 2 interventional study of Tacrolimus Inhalation Powder and Plastiape RS00 Dry Powder inhaler device in Lung Transplant Rejection, sponsored by TFF Pharmaceuticals, Inc.. Terminated at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-06.

Sponsored by TFF Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to funding constraints

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Part A: This is an open label, single-arm study that will evaluate the safety, tolerability, efficacy and PK of Tacrolimus Inhalation Powder over 12 weeks in lung transplant patients who require reduced blood levels of tacrolimus due to kidney toxicity. Tacrolimus Inhalation Powder is being developed as an alternative to oral tacrolimus for prevention of rejection in adult lung transplant recipients.

Part B of this study is an optional safety extension following successful completion of Part A. Patients would have the option to continue Tacrolimus Inhalation Powder for up to 1 year, with a possibility to extend to 2 years pending analysis of Part A data. Participants would return to clinic every 12 weeks for safety assessments, dose adjustments, and to receive more Tacrolimus Inhalation Powder. After 2 years, if the drug is still under development, the subject will be invited to continue receiving Tacrolimus Inhalation Powder under a special access program.

02

Conditions studied

  • Lung Transplant Rejection
03

In context

Lead sponsor

TFF Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written to participate and is willing and able to participate in the study and abide by study restrictions in the judgement of the Investigator.
  2. Males or females aged 18 or over at time of screening.
  3. Continuous non-smoker who has not used nicotine-containing products (including e-vaping) for at least 12 weeks prior to the first dosing and throughout the study, based on patient's self-reporting and urine cotinine levels at screening and Day 1.
  4. Have undergone bilateral allograft lung transplantation at least six months prior to enrolment and meet all of the following:

    1. Receiving oral immediate-release or oral extended-release (not intravenous [IV] or sublingual) tacrolimus at a stable dose for 3 weeks prior to first dosing according to institutional standards as part of an immunosuppressive regimen along with mycophenolate mofetil or azathioprine and
    2. Demonstrating elevated markers of renal dysfunction: blood serum creatinine > 124 μmol/L (0.14 mg/dL) or estimated (eGFR) \< 45
    3. Stable to enable routine post-treatment bronchoscopy with BAL and EBB. is not required in patients with significant increased risk of bleeding after Sponsor Medical Monitor approval.
    4. Screening and forced vital capacity (FVC) values ≥ 40% predicted (to assure viable graft)
  5. Females (women) of (WOCBP) are defined as those who have experienced menarche and who have not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and who are not . WOCBP must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day 1 and must agree to practice as defined below if sexually active with males. In addition, no WOCBP may be planning a pregnancy during the study period.

    1. Female subjects who are WOCBP must agree to use highly effective contraceptive methods or abstinence for the duration of time on the study and continue to use acceptable contraceptive methods for 3 months after administration of the last dose of study treatment. Highly effective contraception is defined as use of the 2-barrier method (e.g., female diaphragm and male condom), 1 barrier method with spermicide, intrauterine device, or hormonal contraceptives (e.g., implant or oral). If the subject is using a hormonal form of contraception, use must have been stable for at least 4 weeks prior to screening.
    2. Abstinence will be acceptable only if it is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation) and withdrawal are not acceptable methods of contraception.
    3. Post-menopausal females are eligible if they meet the definition of menopause (at least 12 months of amenorrhea in the absence of other biological causes) and for females \< 55 years of age, must also have a documented serum follicle stimulating hormone (FSH) level of > 40mIU/mL at Screening.
  6. Male subjects with female partners of childbearing potential must be congenitally sterile or surgically sterile (vasectomy with confirmation of aspermia) or agree to use 2 effective methods of contraception including 1 barrier method (e.g., condom with spermicide and contraception by female partner) for the duration of time on the study and for 3 months after administration of the last dose of study treatment. Use of a condom is required by men during intercourse with a male or female partner to prevent potential delivery of the drug via seminal fluid during the study until the end of treatment visit.
  7. If male, must agree not to donate sperm from the first dosing until 90 days after the last dosing.
  8. Able to successfully perform spirometry, use the inhalation device, and comply with study restrictions and visit schedule.

Exclusion criteria

Exclusion Criteria:

  1. Active antibody-mediated rejection (AMR) or any other evidence of acute rejection
  2. Active bacterial, viral or fungal infection not successfully resolved at least 4 weeks prior to study entry.
  3. Presence of uncontrolled gastro-esophageal reflux disease (GERD)
  4. History or presence of or idiosyncratic reaction to tacrolimus or any calcineurin inhibitor.
  5. Received a treatment with other drug within 5 times the elimination half-life, if known (e.g., a marketed product) or within 30 days (if the elimination half-life is unknown), whichever is longer, prior to Study Day 1 dosing.
  6. Positive for surface antigen (HBsAg) PCR, PCR, and (HIV) I and II antibodies, tuberculosis (TB), or COVID-19 at Screening.
  7. Patients who have taken any of the following prohibited medications within 30 days of the first dose or who are expected to require these medications during the study:

    1. Cyclosporin
    2. Any form of sirolimus or everolimus
  8. Allergy or sensitivity to lactose or milk products.
  9. hepatic impairment defined as 5 times the (ULN) for and AST.
  10. Patients receiving haemodialysis or peritoneal dialysis
  11. Active post-transplant lymphoproliferative disorder (PTLD) related to Epstein-Barr Virus (EBV) infection.
  12. Subjects with significant (ECG) abnormalities at screening, including a corrected by the Fridericia correction formula that is ≥ 440 msec in men and ≥ 460 msec in women.
  13. Demonstrates an inability to operate the inhalation device after training.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Tacrolimus Inhalation Powder

    Single arm open label

    Drug: Tacrolimus Inhalation Powder · Device: Plastiape RS00 Dry Powder inhaler device

Interventions

  • Tacrolimus powder for inhalation to prevent acute allograft rejection

    Also known as: Tacrolimus

  • DevicePlastiape RS00 Dry Powder inhaler device

    dry powder inhaler device

06

What researchers measure

Primary outcomes

  1. Effect on renal function

    Mean change from baseline in renal function (glomerular filtration rate and creatinine) over time.

    Time frame: Baseline through 12 weeks

  2. Incidence of treatment-emergent AEs, serious adverse events (SAEs), and withdrawals due to AEs.

    safety and tolerability

    Time frame: baseline through 12 weeks

  3. Change in systolic and diastolic blood pressure (mm Hg) over time

    safety and tolerability

    Time frame: baseline through 12 weeks

  4. Changes from baseline in potassium (mEq/L) over time

    safety and tolerability

    Time frame: baseline through 12 weeks

  5. Changes from baseline in forced expiratory volume in one second (FEV-1) in liters

    safety and tolerability

    Time frame: baseline through 12 weeks

  6. Changes from baseline in chest radiography

    safety and tolerability

    Time frame: baseline through 12 weeks

  7. Number of participants with changes from baseline in physical examinations

    safety and tolerability

    Time frame: baseline through 12 weeks

  8. Proportion of patients meeting treatment stopping rules.

    safety and tolerability

    Time frame: baseline through 12 weeks

  9. Incidence of all-cause mortality and allograft-related mortality.

    safety and tolerability

    Time frame: baseline through 12 weeks

  10. Incidence of all-cause hospitalization and allograft-related hospitalization

    safety and tolerability

    Time frame: baseline through 12 weeks

  11. Efficacy of Tacrolimus Inhalation Powder in preventing acute rejection events

    Proportion of patients with no evidence of allograft rejection.

    Time frame: Baseline through 12 weeks

  12. Efficacy of Tacrolimus Inhalation Powder in preventing acute rejection events

    Median time to first evidence of rejection.

    Time frame: Baseline through 12 weeks

  13. Tacrolimus maximum concentration (Cmax) by visit

    Pharmacokinetics

    Time frame: baseline through 12 weeks

  14. Tacrolimus time to maximum concentration (Tmax) by visit

    Pharmacokinetics

    Time frame: baseline through 12 weeks

  15. Tacrolimus area under the curve from 0 to 6 hours (AUC0-6) by visit.

    Pharmacokinetics

    Time frame: baseline through 12 weeks

  16. Tacrolimus area under the curve to last measurement (AUClast) by visit.

    pharmacokinetics

    Time frame: baseline through 12 weeks

  17. Therapeutic drug monitoring tacrolimus blood levels by visit

    Pharmacokinetics

    Time frame: baseline through 12 weeks

Secondary outcomes

  1. Blood and BAL biomarkers

    Ratio of BAL:Blood tacrolimus trough levels at Visit 1b and Visit 9b after oral and inhaled administration, respectively, and change in ratio.

    Time frame: Baseline through 12 weeks

  2. DSA

    Donor-specific antibody levels (DSA) at baseline on oral tacrolimus and after treatment with Tacrolimus Inhalation Powder.

    Time frame: Baseline through 12 weeks

  3. Acute allograft rejection from EBB samples

    To determine if Tacrolimus Inhalation Powder reduces (if elevated) or maintains (if already low) signs of acute allograft rejection from endobronchial biopsy (EBB) samples compared with baseline oral tacrolimus therapy.

    Time frame: Baseline through week 12

07

Study locations

2 sites
  • St Vincent's Hospital
    Darlinghurst, New South Wales 2010, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Oct 2024, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2022
First posted
Aug 15, 2022
StartActual
Apr 18, 2023
Primary completionActual
Oct 29, 2024
CompletionActual
Dec 23, 2024
Last update
Jan 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05501574
Lead sponsor
TFF Pharmaceuticals, Inc.
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Aug 15, 2022
Start date
Apr 18, 2023
Primary completion
Oct 29, 2024
Completion
Dec 23, 2024
Last update
Jan 6, 2025

Study contacts

Zamaneh Mikhak, MD
study director · TFF Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion